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Protective role of nitric oxide in mice with Shiga toxin-induced to a pathological cascade that may involve the produc-
hemolytic uremic syndrome. tion of nitric oxide (NO), prostacyclin (PGI2), platelet-
Background. Nitric oxide (NO) is an endogenous vasodila- activating factor (PAF), von Willebrand factor and in-tor and platelet inhibitor. An enhanced NO production has
terleukins (ILs) [2, 3]. In humans, the kidney is the pri-been detected in patients with hemolytic uremic syndrome
mary target, probably due to high basal level of Gb3.(HUS), although its implication in HUS pathogenesis has not
been clarified. The typical renal histologic finding is a characteristic
Methods. A mouse model of Shiga toxin 2 (Stx2)-induced glomerular thrombotic microangiopathy (TMA); the
HUS was used to study the role of NO in the development of glomerulus appears wrinkled, with endothelial cell swell-
the disease. Modulation of l-arginine-NO pathway was achieved
ing and capillary wall thickening, and the lumen of theby oral administration of NO synthase (NOS) substrate or inhibi-
capillaries is largely obstructed by fibrin thrombi [2, 4].tors, and renal damage, mortality and platelet activity were
evaluated. The involvement of platelets was studied by means A characteristic pattern of impaired platelet function is
of a specific anti-platelet antibody. found in most patients with HUS. This impairment con-
Results. Inhibition of NO generation by the NOS inhibitor sists in thrombocytopenia, shortened survival of re-
L-NAME enhanced Stx2-mediated renal damage and lethal- maining circulating platelets, abnormal response to ag-ity; this effect was prevented by the addition of l-arginine.
gregating agents, platelet exhaustion and pathologicalThe worsening effect of L-NAME involved enhanced Stx2-
platelet microthrombi found in the kidney [2, 5–8], andmediated platelet activation, and it was completely prevented
by platelet depletion. it is thought to be a consequence of previous endothelial
Conclusions. NO exerts a protective role in the early patho- damage-induced platelet activation, since the platelet
genesis of HUS, and its inhibition potentiates renal damage and content of specific granules is markedly reduced [6, 8].mortality through a mechanism involving enhanced platelet
Nitric oxide is an endogenously produced vasodilator,activation.
the cellular effects of which are signaled via stimulation
of 3,5-guanosine monophosphate (cGMP) [9]. NO is
also a well known inhibitor of platelet function. AmongHemolytic uremic syndrome (HUS) is characterized
its effects, inhibition of platelet aggregation and adhe-by hemorrhagic diarrhea followed by microangiopathic
sion to damaged endothelium as well as inhibition ofhemolytic anemia, thrombocytopenia and acute renal
P-selectin expression and fibrinogen binding to plateletsfailure. Shiga toxin (Stx) producing Escherichia coli has
have been described [10, 11]. There are several clinicalbeen strongly associated with outbreaks of the disease [1].
studies on the enhanced NO production in patients dur-The toxin binds to a globotriaosil ceramide (Gb3) recep-
ing the active phase of HUS [12–14]; however, its roletor and interferes with protein synthesis, mainly on capil-
in the pathogenesis of the syndrome has not yet beenlary endothelial cells. In addition, the injured endothe-
assessed, and whether it exerts a protective or a detri-lium loses its anti-thrombogenic properties, thus leading
mental effect remains controversial. Due to its anti-
thrombogenic properties, it has been hypothesized that
treatment with oral l-arginine, the physiological precur-Key words: pathogenesis of HUS, hemorrhagic diarrhea, platelet acti-
vation, thrombocytopenia, acute renal failure. sor of NO, could provide an alternative clinical approach
to the control of HUS [15]. On the other hand, NO is aReceived for publication August 28, 2001
potent cytotoxic agent that could mediate vascular injury.and in revised form March 29, 2002
Accepted for publication May 1, 2002 Thus, an up-regulation of NO production could enhance
vessel wall damage and vascular dysfunction [13, 16–18]. 2002 by the International Society of Nephrology
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The Stx-treated mouse is a widely used model to study dilutions of the samples containing Stx2 were added to
each well (25,000 Vero cells) and incubated for threethe clinical and histopathological changes associated
with human HUS, in which gastrointestinal, neurologic days at 37C in 5% CO2. Vero cells were daily ex-
amined for cytotoxicity. The 50% cytotoxic dose (CD50)and systemic symptoms have been reproduced [19–25].
In the mouse kidney, histological damage has been docu- corresponded to the dilution required to kill 50% of the
Vero cells: CD50 was 0.063 pg.mented as taking place mainly in renal tubules and to a
lesser degree in glomeruli. The toxin produces severe acute
Stx2 treatmentrenal cortical tubular necrosis [19–25] and glomerular
mesangial proliferation and fibrinogen deposition as well Mice were intravenously injected with a dose of Stx2
required to kill 50% of mice (LD50). Our previous studyas vascular congestion and interstitial inflammation [25].
However, to date no glomerular thrombotic lesions char- evaluated the in vivo lethality of Stx2 by serial dilutions
in pyrogen-free saline [26]. The LD50 was approximatelyacteristic of human HUS have been noticed in mice [25].
In this study we have used an HUS model of Stx2- 2.5  105 mg/kg body weight (500 pg/mouse), for which
the mean time of death was 3.5 days. The same batch ofinjected mice [26, 27] to determine the role of endoge-
nously synthesized NO in the pathology of the syndrome. Stx2 preparation was used throughout the experiments.
We demonstrate that Stx2-induced renal toxicity and mor-
NO synthase (NOS) modulationtality are markedly enhanced by inhibition of the endoge-
nous NO production. The underlying mechanism involves In all protocols, solutions of the NOS inhibitors NG-nitro-
L-arginine methyl ester (L-NAME; Sigma Chemical Co.),increased platelet activity and thrombus formation.
L-N6-(1-imino-ethyl)-lysine (L-NIL; Calbiochem-Nova-
biochem Corp., San Diego, CA, USA), and aminoguani-
METHODS
dine (AG; Sigma), the D-form of L-NAME (D-NAME;
Mice Sigma) and the physiological substrate for the enzyme
l-arginine (L-ARG; Sigma) were freshly prepared everyBALB/c mice were bred in the animal facility at the
Departamento de Medicina Experimental, Academia Na- two days, administered via the drinking water and con-
sumed ad libitum. The final concentrations used were:cional de Medicina, Buenos Aires. Male mice aged 8 to
16 weeks and weighing 20 to 24 g were used throughout L-NAME and D-NAME, 1 mg/mL; L-NIL, 10 mmol/L;
AG, 100 g/mL; L-ARG, 10 mg/mL. Treatments beganthe experiments. They were maintained under a 12-hour
light/dark cycle at a temperature of 22  2C and fed 24 hours prior to the injection of Stx2 and lasted until
the end of the experiments, inducing no detectable varia-with standard diet and water ad libitum. The experiments
performed herein were conducted according to princi- tions in the NOS activity as assessed by NO production
herein and in previous reports. Similarly, these treat-ples set forth in the Guide for the Care and Use of
Laboratory Animals (National Institute of Health, 1985). ments did not influence water or food intake or impair
weight gain in naive mice [29–32].
Stx2 preparation
Nitric oxide assayStx2 was kindly provided by Dr. Sugiyama Junichi
from Denka Seiken Co., Ltd. (Nigata, Japan). Purity was The concentration of the anions NO2 and NO3 in
plasma was used as a quantitative measure of NO pro-analyzed by the supplier showing only one peak in high
pressure liquid chromatography (HPLC). Stx2 prepara- duction. A commercially available kit for total NO deter-
mination (R & D Systems, Inc., Minneapolis, MN, USA)tion was checked for endotoxin contamination by the
Limulus amoebocyte lysate assay given that 1 IU/mL is was employed. Briefly, the assay determined total NO
based on the enzymatic conversion of nitrate to nitriteequal to 0.1 ng/mL of United States Pharmacopea stan-
dard E. coli endotoxin. Stx2 preparation contained less by nitrate reductase. The reaction was followed by the
colorimetric detection at 540 nm of the azo dye productthat 40 pg lipopolysaccharide (LPS)/g of Shiga toxin
protein. Stx2 was tested for cytotoxic activity on Vero of the Griess reaction (50 L samples plus an equal
volume of Griess reagent consisting of 1% sulfanilamide,cells as previously described [28] in the Instituto Nacional
de Enfermedades Infecciosas, ANLIS “Dr. C.G. Mal- 0.1% naphthylethylene diamine dihydrochloride, and
2.5% H3PO4).bra´n,” Buenos Aires, Argentina. Briefly, Vero cells were
grown in Eagle’s minimum essential medium with Earle
Plasmatic urea determinationsalts and non-essential amino acids (Gibco Diagnostics,
Madison, WI, USA) supplemented with 7% fetal calf Blood was obtained by puncture of the retroorbital
plexus. Biochemical determinations of urea in serumserum (FCS; Sigma Chemical Co., St. Louis, MO, USA),
0.03 mol/L glutamine, 50 g/mL gentamicin and 2.5 were performed in an autoanalyzer CCX Spectrum (Ab-
bott Diagnostics System, Buenos Aires, Argentina) fol-g/mL fungizone in microtiter plates (Nunc, Intermed,
Roskilde, Denmark). Aliquots (50 L) of serial two-fold lowing standardized instructions.
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Histological studies Flow cytometry studies
Mepacrine staining was detected as previously out-Animals from the control and experimental groups
lined [33]. Briefly, PRP was incubated at 3C in the darkwere sacrificed 72 hours after Stx2 injection and sub-
for 30 minutes in 0.1 mmol/L quinaqcrine mustard (mep-jected to necropsy. Both kidneys from each mouse (8
acrine; Sigma) and then washed twice in CGS bufferper group) were longitudinally bisected and fixed in 10%
(0.109 mol/L trisodium citrate, 30 mmol/L glucose, 0.15neutral formalin and routinely processed. Sections of
mol/L sodium chloride). For each sample a second ali-paraffin-embedded tissue were stained with hematoxylin
quot of platelets was simultaneously incubated withoutand eosin (H&E) and periodic acid-Schiff (PAS) and
stain and used as a negative control. Mepacrine-loadedexamined by light microscopy. Glomerular injury was
platelets were resuspended in CGS buffer to a concentra-evaluated by the presence of hypercellularity, crescent
tion of 200  105 cells/L for flow cytometry, and kept information and thrombosis. Tubular injury was evaluated
the dark until analyzed. A Beckton Dickinson FACScanby the presence of alterations in tubular epithelium,
configured for FITC emission at a range of 520 to 530 nmbasement membrane integrity and necrosis. Vascular in-
was used to detect the mepacrine. The platelet popula-terstitial congestion also was assessed.
tion was gated by the distinct pattern on the histogram of
log forward scatter versus log side scatter. An analysis re-Immunostaining for fibrinogen
gion was set from log 1 of the fluorescence scale, and per-Another set of kidney sections was stained for fibrin-
centages of mepacrine-positive gated cells were compared.ogen using an immunoperoxidase method. Endogenous
peroxidase was blocked with 0.5% hydrogen peroxide in Platelet depletion studies
methanol. Sections were then exposed to rabbit anti-
Platelet rich plasma from control BALB/c mice werehuman fibrinogen, which cross-reacts with mouse fibrin-
obtained as stated above and washed twice. Adult rabbitsogen (Dako Corp., Carpinteria, CA, USA) at 1:50. For
were injected IV with a suspension of 1  109 platelets
detection, a commercial kit (Dako LSAB 2-System HRP-
per dose at days 1, 10, 20 and 30. At day 40, animals
DAB) was employed. Counterstaining was done with were bled by puncture of the ear vein and serum was
hematoxylin. Glomeruli showing thrombi by fibrinogen maintained at 20C. Rabbits were boosted monthly.
staining were counted and expressed as percentage (N In preliminary experiments we determined that an IP
100 40 magnification fields). injection of 100 L of a 1:2 dilution of the antiserum
induced an almost complete depletion of mice plateletsPlatelet aggregation studies
four hours after the injection (No platelets  103/L,
Blood samples were obtained from each mouse by 899  15 for control and 7  0.2 for treated mice).
retro-orbital punction. Nine volumes of whole blood were Similar platelet depletion was maintained throughout
gently mixed in a polyethylene tube with one volume of a the experiments by a first injection of the antiserum
3.8% (wt/vol) trisodiun citrate solution in water. Platelet- four hours before Stx2 administration and successive
poor plasma (PPP) was prepared by centrifugation of injections every 12 hours.
the blood at 1000 g for 20 minutes at 4C, and platelet-
Statistical analysisrich plasma (PRP) was obtained by centrifugation of the
blood at 300  g for 20 minutes at room temperature. All data correspond to the mean  SEM of individual
For more accurate comparison, PRPs from control and mice. Statistical differences were determined using the
experimental groups were adjusted with autologous PPPs one-way analysis of variance (ANOVA), and P 0.05 was
to achieve comparable platelet counts. Aggregation stud- considered significant. Individual groups were compared
ies were performed using a Chrono-log whole blood using the unpaired Student t test. Significance in survival
lumi-aggregometer [Ca2]. Briefly, 450 L of PRP were experiments was evaluated by the Fisher exact test.
added with a stirring bar to a glass cuvette and were al-
lowed to warm at 37C prior to the addition of the ago-
RESULTSnists. Light transmission was adjusted to 10% for PRPs
Effect of NO modulation on Stx2-induced lethalityand to 90% for PPPs. At time zero, the aggregating agents
were added in 50 L volumes. Platelet aggregation re- The effect of NO modulation on Stx2 toxicity was
sulted in an increased light transmission and upward evaluated through mortality rates. Groups of six mice
deflection of the recording curve. Adenosine diphos- were treated orally with NOS inhibitors or substrate,
phate (ADP) and arachidonic acid (AA) were purchased and 24 hours later were injected intravenously with 500
from Sigma. ADP and AA were dissolved in saline to pg/mouse (LD50) of purified Stx2. Survival data shown
a final concentration of 2.5mol/L and 0.5 mmol/L, re- in Figure 1A indicate that pretreatment of mice with
L-NAME enhanced the lethal toxicity of Stx2. The meanspectively.
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Fig. 1. Effect of nitric oxide (NO) modulation on Shiga toxin 2 (Stx2)-induced lethality. (A) Effect of L-NAME modulation upon Stx2-induced
lethality. Groups of six mice were treated with nothing, L-NAME, D-NAME, L-NIL or AG from time 24 hours until the end of the experiment.
At time 0, mice were intravenously injected with 500 pg of Stx2; time of death was evaluated up to 150 hours after Stx2 injection. Pooled survival
percentages corresponding to seven separate experiments are shown. (*P  0.01, compared to Stx2). (B) Reversibility of L-NAME–induced
increment in Stx2-mediated mortality by the NOS substrate, L-ARG (*P  0.05, compared to Stx2	L-NAME	L-ARG, N  10).
time to death ( SEM) for Stx2 and Stx2	L-NAME-
treated mice was 121.9 5.2 and 91.2 2.1 hours, respec-
tively (P  0.01). The mortality rate for mice treated
with Stx2 plus the inactive enantiomer D-NAME did
not differ from that of Stx2-treated mice. On the other
hand, administration of aminoguanidine (AG) or L-NIL,
both selective inducible NOS (iNOS) inhibitors, did not
affect Stx2 toxicity. We next determined the effect of
the physiological substrate of NOS, L-ARG. As shown
in Figure 1B, L-ARG was able to prevent L-NAME-
mediated potentiation of Stx2 toxicity when adminis-
tered together; L-ARG alone, however, exerted no sig-
nificant effect (data not shown).
Urea levels in plasma
Our previous report on mice inoculated with one LD50
of Stx2 showed an increase in plasmatic urea at 72 hours
after injection, consistent with renal damage [26]. To Fig. 2. Plasmatic urea variation induced by Stx2 and L-NAME. Mice
were bled at different times after Stx2 injection. Data are from oneascertain whether NOS inhibition enhanced Stx2 toxicity
representative experiment out of five, and show mean  SEM of plas-by increasing its specific renal damage, animals from the matic urea values from 10 mice/group (*P  0.01, compared to con-
different groups were bled at 48, 72 and 96 hours post- trols; #P  0.01, compared to Stx2, to L-NAME and to Stx2	
L-NAME	L-ARG).Stx2 injection, and the level of plasmatic urea was deter-
mined. As shown in Figure 2, all Stx2-treated mice dis-
played abnormal renal function, evidenced by elevated
rates. Since it is well known that chronic administrationuremia (range 86 to 380 mg%), compared to controls
with L-NAME can modify renal function, we also mea-(range 47 to 54 mg%). The L-NAME pretreated animals
sured urea in plasma of mice given only L-NAME (rangedisplayed significantly higher urea levels at 72 and 96
39 to 58%), and detected no differences compared tohours, compared to the Stx2 group, which were consis-
tent with the above mentioned increment in mortality the control group. Again, when administered together
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Fig. 3. Histology of kidneys from Stx2-treated animals (H&E, PAS staining). (A) Renal cortical tissue showing mild glomerular mesangial
hypercellularity and crescent formation. Glomerular capillaries with mild incipient thrombus formation (400). (B) Cortical tubular epithelial cell
swelling. Tubular cells with loss of apical microvilli and tubular basement membrane shrinkage (400).
with L-NAME, L-ARG was able to prevent the L-NAME- ure 5A shows the percentage of compromised glomeruli
for every experimental group. In mice treated with Stx2mediated potentiation of Stx2-induced renal toxicity. It
can be postulated that the inhibition of NO production en- almost half of the glomeruli were affected; fibrinogen
deposition appeared either adhered to the vessel wallhanced Stx2-induced mortality by potentiating renal injury.
or occluding the lumen (Fig. 5B). A marked increase in
Histological examination the thrombosis phenomenon was seen in the Stx2	
L-NAME group, where almost every glomerulus pre-The H&E and PAS stainings revealed in the Stx2
group a moderate to severe widespread glomerular mes- sented fibrinogen deposition in the same pattern de-
scribed above (Fig. 5C). L-ARG, administered alongangial hypercellularity and crescent formation (Fig. 3A)
with tubular epithelial swelling and disrupted basement with L-NAME, induced a degree of thrombosis similar
to that observed in the Stx2-treated group, thus pre-membrane in proximal cortex (Fig. 3B). In the Stx2	
L-NAME group, glomerular thrombosis was diffusely dis- venting the effect of L-NAME (data not shown). In all
groups thrombosis was not confined to glomerular mi-tributed throughout the cortex (Fig. 4A). A detail shows a
glomerulus with deposits of hyaline, PAS-positive amor- crocirculation, but occasionally extended to interstitial
capillaries. Neither control nor L-NAME-treated micephous material in the glomerular tufts (Fig. 4B), consis-
tent with capillary thrombosis [34, 35]. Severe tubular showed any sign of thrombosis (data not shown).
epithelial cell damage with loss of basement membrane
Stx2 and L-NAME effects on platelet activationoccurred in proximal and distal tubules of the cortex,
leading to widespread necrosis (Fig. 4 A, C, D). Kidneys Increased platelet activity and thrombus formation
would account for Stx-induced renal damage in patientscorresponding to the Stx2	L-NAME	L-ARG group
showed a lesser degree of renal damage; there were di- with HUS. Since NO is an active platelet inhibitor, we
evaluated the possibility that inhibition of its synthesislated glomerular capillaries with incipient hyaline amor-
phous deposits, and no evidence of epithelial cell necrosis could potentiate Stx2-mediated lethality by enhancing
platelet activation. Table 1 summarizes platelet countsin tubules (data not shown).
Kidneys from mice treated only with L-NAME showed of control and experimental animals at 12 and 24 hours
after Stx2 injection. At an early period (12 hours), thesignificant dilated glomerular capillaries and interstitial
platelet number was elevated in the Stx2-treated group,vascular congestion, which probably reflect the hemody-
and L-NAME significantly enhanced this effect. At 24namic changes associated to the vasoconstrictor effect
hours, however, both Stx2 and Stx2	L-NAME-treatedof L-NAME. In this group epithelial cells in nephron
mice showed thrombocytopenia, which persisted up tosegments were normal in appearance (data not shown).
72 hours. To study the functional status of platelets, ag-Kidneys from control mice lacked histological changes
gregation studies were performed. We assayed currently(data not shown).
used platelet agonists such as arachidonic acid (AA) and
Immunostaining for fibrinogen ADP, which induced a rapid aggregative response. Per-
centages of aggregation against AA are shown in Fig-The presence of thrombi inside glomerular capillaries
was assessed by a specific staining for fibrinogen. Fig- ure 6A. Platelets from Stx2-treated animals were acti-
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Fig. 4. Histology of kidneys from Stx2	L-NAME-treated animals (H&E, PAS staining). (A) Cortical renal tissue with glomeruli and proximal
cortical tubules showing a widespread severe damage (250). (B) Glomeruli with hypercellularity, crescent formation and evident capillary
thrombosis, surrounded by cortical tubules with acute epithelium necrosis (400). (C ) Distal cortical tubules with severe necrosis of tubular
epithelium and dilated interstitial capillaries (250). (D) Loss of tubular architecture due to severe and broad necrosis (400).
vated at 24 hours post-Stx2 injection, while in Stx2	 noted by cell counts and aggregative response, and that
inhibition of NO production by L-NAME potentiatedL-NAME-treated mice activation was achieved earlier
(12 hours). This activation was followed by an inhibited this activation. As another marker of platelet activation,
platelet intracellular ADP granule content was measuredresponse in both groups, probably reflecting platelet ex-
haustion. A similar pattern was observed when ADP by means of a cytometric technique. First, the mepacrine
staining in platelets was evaluated both in controls andwas used as agonist (Fig. 6B). Platelets from Stx2 and
Stx2	L-NAME-treated animals were clearly activated Stx2-treated mice at different times after the Stx2 injec-
tion. As shown in Figure 7A, a significant reduction inat 24 hours. This activation resulted in inhibition at 48
and 72 hours in both groups, although inhibition in Stx2	 granule content was observed in the Stx2 group at 48
and 72 hours. At this Stx2 concentration, however, noL-NAME group was markedly higher. Taken together,
these results suggest that Stx2 treatment elicited platelet difference could be appreciated between the Stx2 and the
Stx2	L-NAME groups (data not shown). To elucidateactivation, which was rapidly followed by cessation and
inhibition. Both activation and inhibition responses were whether L-NAME pretreatment was able to further en-
hance Stx2 action, we then used a lower dose of Stx2achieved earlier in the Stx2	L-NAME-treated animals,
indicating that NO suppression further enhanced Stx2- (300 pg/mouse), at which Stx2 by itself exerted no effect
on platelet degranulation. Results shown in Figure 7Bmediated platelet activation.
indicate that Stx2	L-NAME-induced degranulation be-
NO inhibition potentiated Stx2-induced came evident, thus suggesting that L-NAME pretreat-
platelet degranulation ment was able to potentiate Stx2-mediated degranula-
tion. Again, the effect of L-NAME was prevented byThe previously mentioned data indicated that Stx2
treatment was able to induce platelet activation, as de- L-ARG addition. It is worth noting that neither L-NAME
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Fig. 5. Immunostaining for fibrinogen. (A) A mean number of 100
fields (40) was counted and the percentage ( SEM) of glomeruli
positively stained for fibrinogen was determined for every experimental
group (*P 0.001, compared to controls and to L-NAME; #P 0.0125,
compared to Stx2 and to Stx2	L-NAME	L-ARG). (B) Renal section
from Stx2-treated mice, showing 1 out of 4 glomeruli positively stained
for fibrinogen (arrow) (250). The inset shows that the antifibrinogen
antibody has specifically detected thrombosis in glomerular capillaries
(400). (C ) Renal section from Stx2	L-NAME-treated mice, where
every glomerulus is positively stained (250). The insert shows a glo-
merulus with highly stained material in the vessel wall and occluding
the lumen (400).
Table 1. Alteration in platelet counts induced by Stx2 and L-NAME the absence of platelets. On the contrary, the worsening
effect of L-NAME upon Stx2 toxicity was abolished inTime
hours Control Stx2 Stx2	L-NAME the platelet depleted mice, suggesting that this effect was
12 8.460.18 13.120.67a 17.800.24ab mediated, at least in part, by platelets. These results in-
24 8.660.43 6.410.35a 5.930.45a dicate that there is a deleterious basal effect exerted by
72 8.580.66 6.960.29a 5.510.71a
Stx2 itself that operates independently of platelets; in
Data are expressed as platelet counts  105 per L (mean  SEM). Platelet contrast, this cell population might be involved in thenumber was determined in platelet rich plasma (PRPs) of control (N  5) and
treated (N  7) animals, at different times after Stx2 injection. enhancing action of L-NAME, probably through the for-
a P  0.01, compared to controls mation of thrombi.b P  0.02, compared to Stx2
Stx2 induced the generation of NO metabolites
To evaluate whether Stx2 injection modified the
nor L-ARG by themselves induced any change in plate- L-ARG-NO pathway activity in the mouse model, NO
let activation or degranulation. generation was measured as total NO2 plus NO3 concen-
tration in sera of control and treated mice, at different
Platelet participation in Stx2 and L-NAME action times after Stx2 injection. At 12 and 24 hours post-Stx2,
no variations were detected in the NO concentrationThe involvement of platelets in the effect of Stx2 and
(data not shown). However, at 48 hours, treatment withStx2	L-NAME treatments was evaluated in animals in
which the platelet population was removed by means of a Stx2 significantly enhanced basal production of NO (Ta-
ble 2); pretreatment with L-NAME was able to preventspecific polyclonal antiserum obtained in rabbit. Figure 8
shows that Stx2-mediated mortality was not modified by this Stx2-mediated effect. Oral administration of L-NAME
Dran et al: NO protects against Stx toxicity in HUS 1345
Fig. 6. Platelet aggregative response against (A) arachidonic acid (AA) (B) or adenosine diphosphate (ADP). Results are from one representative
experiment out of five and are expressed as the percentage of aggregation compared to control (100%). Platelet rich plasma (PRP) from controls,
Stx2 and Stx2	L-NAME-treated mice were obtained at different times after Stx2 injection and incubated with AA (final concentration: 0.5
mmol/L) or ADP (final concentration: 2.5 mol/L). *P  0.01, compared to controls; #P  0.05, compared to Stx2.
Fig. 7. Mepacrine staining in platelets from Stx2- and Stx2	L-NAME-treated animals (A). Symbols are: ( ) saline; ( ) Stx2. Mice were bled
daily at different times after Stx2 injection (500 pg/mice). Mepacrine staining was determined by flow cytometry. Each bar represents the mean
percentage of mepacrine positive cells (% MPC)  SEM of six mice from one representative experiment out of five (*P  0.01, compared to
controls, saline injected animals) (B). Percentages of MPC at 48 hours after Stx2 injection (300 pg/mice) corresponding to six mice of a representative
experiment out of three (*P  0.05, compared to saline, to Stx2 and to Stx2	L-NAME	L-ARG-treated groups).
at the present concentrations did not cause evident varia- named “platelet exhaustion” has been detected along
with thrombocytopenia in most of the hospitalized pa-tions in basal serum concentration of NO by itself, in
tients. This impairment consists of a reduced aggregativeagreement with previous reports [29, 30]. As stated for
response, depletion in platelet granule content and short-humans, we were able to detect a late Stx2 induction of
ened platelet survival [6, 8], and is interpreted as the con-NOS activity in mice.
sequence of a prior phase of endothelial damage-induced
platelet activation. This concept is supported by many
DISCUSSION biochemical findings, such as increased plasma levels of
Every step in the pathogenic cascade resulting from platelet derived factors and reduced intraplatelet nucleo-
the invasion of the host by Stx-producing E. coli and tides, serotonin and thromboxane A2 [8, 11, 36–38].
leads to the final event of microvessel thrombosis in The mouse model used herein allowed an examination
HUS, remains elusive. It has been suggested that platelet of the first stages in the development of HUS and permit-
activation may be responsible for some of the clinical ted the demonstration that Stx2 induces an early platelet
features. However, the occurrence of platelet hyperactiv- activation, as denoted by a higher cell count, enhanced
ity has not been demonstrated, probably because it is a aggregative response to different agonists and degranu-
lation. This activation is rapidly followed by inhibition,very early event. Instead, an impaired platelet function
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Table 2. Generation of NO metabolites by Stx2
[NO2] in serum
Treatment mmol/L X  SEM N
None 5.11.1 12
Stx2 9.43.0a 12
L-NAME 4.90.7b 12
Stx2	L-NAME 5.22.3b 12
Total nitrite concentration ([NO2]) was measured in sera of animals treated
with Stx2, L-NAME or Stx2	L-NAME, 48 hours after Stx2 injection.
a P  0.05
b Non-significant, compared to controls
in the proximal and distal tubular epithelium, whereas
the addition of L-ARG prevented this effect. On the
other hand, kidneys from mice receiving only L-NAME
displayed unaltered tubular epithelial architecture, with
dilated intraglomerular capillaries and cortical intersti-
tial vascular congestion. It is important to point out that
Fig. 8. Stx2 and Stx2	L-NAME lethality in mice depleted from plate- these alterations could be attributed to the vasoactive ef-
lets. Groups of six mice were injected with a rabbit polyclonal antiserum fect of L-NAME and are unlikely to be responsible per seagainst mouse platelets (Ab), to induce significant reduction in platelet
for the increase in plasmatic urea, renal injury and mortal-number. Then mice received Stx2 or Stx2	L-NAME as detailed before.
Pooled survival percentages corresponding to 18 animals are shown ity after L-NAME treatment of Stx2-injected mice. This
(*P  0.05; **P  0.01, compared to Stx2	Ab	L-NAME). leads us to postulate that L-NAME–mediated effects
reflect a real worsening of renal damage induced by Stx2
instead of a hemodynamic phenomenon.
In the kidney, neuronal NOS in the macula densa andconsistent with the platelet exhaustion described in hu-
mans. It is noteworthy that the results from the platelet endothelial constitutive NOS (ecNOS) are involved in
the regulation of glomerular hemodynamics; in additiondepletion studies indicate that a severe antibody-induced
thrombocytopenia does not prevent Stx2 lethality. This there is iNOS, which is specifically activated during in-
flammation [39]. Since L-NAME is a non-specific NOSsuggests that platelet activation constitutes a worsening
modulation factor operating within Stx2-induced patho- inhibitor [40], we tested the effect of two selective iNOS
inhibitors, AG and L-NIL. The observation that neithergenicity.
Despite evidence of the activation of NO pathway AG (which is 100-fold more potent than L-NAME) nor
L-NIL, a highly potent murine iNOS inhibitor [41], ex-during HUS [12–14], the actual role of NO in the patho-
genesis of the illness is still controversial [11, 13–18]. erted any effect on Stx2-induced lethality indicates that
the constitutive isoform of NOS would be preferentiallyWe investigated the potential pathophysiological role of
endogenous NO in Stx2 toxicity by blocking its produc- involved in the deleterious effect of L-NAME. In sum-
mary, these results suggest that cNOS releases NO,tion by means of NOS inhibitors. The NOS inhibitor
L-NAME enhanced Stx2-stimulated renal damage and which is capable of ameliorating Stx2-induced injury by
reducing Stx2-mediated platelet aggregation, raising themortality. Moreover, L-NAME accelerated and ampli-
fied the Stx2-induced pattern of platelet activation fol- possibility that NO could be a physiological regulator
for platelet dysfunction and thrombus formation in HUS.lowed by platelet exhaustion, as assessed by the higher
number of circulating platelets, earlier achieved aggre- This is in agreement with the general concept stating
that moderate amounts of NO released by cNOS play agative response and enhanced degranulation. In favor
of platelet activation contributing to the pathogenicity homeostatic role; conversely, high concentrations of NO
resulting from the output of iNOS usually lead to tissueof Stx2, it can be postulated that the inhibition of NO
synthesis enhances renal damage and leads to death, at injury. In HUS, an excessive NO release has been associ-
ated with the secretion of inflammatory mediators (suchleast in part, by potentiating the platelet activity and the
consequent thrombus formation. In fact, the enhanc- as TNF-
, IL-1) and the generation of highly cytotoxic
radicals [18].ing effect of L-NAME is not observed in thrombocyto-
penic mice. In keeping with our results, beneficial effects of NO
have been demonstrated in a rat model for endotoxemiaHistological findings strengthen this hypothesis since
pretreatment of mice with L-NAME aggravated Stx2- [42], where NO is important in maintaining renal perfu-
sion and preventing endotoxin-induced platelet aggre-induced renal alterations, and led not only to widespread
glomerular thrombosis, but also to extensive necrotic areas gation and thrombosis in glomeruli during shock [43].
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A presumed protective role for NO in HUS also has APPENDIX
been theorized by Jaradat and Marquardt [15], who pro-
Abbreviations used in this article are: AA, arachidonic acid; ADP,
posed that oral administration of l-arginine could gener- adenosine diphosphate; AG, aminoguanidine; CD50, 50% cytotoxic dose;
cGMP, cyclic 3,5-guanosine monophosphate; D-NAME, D-nitro-ate NO, which in turn would decrease platelet aggrega-
L-arginine methyl ester; Gb3, globotriaosil ceramide; E. coli, Esche-tion and increase vasodilation. To our knowledge, only
richia coli; H&E, hematoxylin and eosin (stain); HPLC, high pressure
one experimental protocol exists in which one patient liquid chromatography; HUS, hemolytic uremic syndrome; iNOS, in-
ducible nitric oxide synthase; IL, interleukin; L-ARG, l-arginine; LD50,undergoing the acute phase of thrombotic thrombocyto-
lethal dose 50%; L-NAME, L-NG-nitro-L-arginine methyl ester; L-NIL,penic purpura (TTP), a disease closely related to HUS, L-N6(1-imino-ethyl)-lysine; NO, nitric oxide; NO2 , nitrite; NO3 , ni-
received oral l-arginine and experienced a lower number trate; NOS, nitric oxide synthase; PAS, periodic acid Schiff (stain);
PGI2, prostacyclin; PPP, platelet poor plasma; PRP, platelet richof relapses [14]. These authors outlined the importance
plasma; Stx2, Shiga toxin 2; TMA, thrombotic microangiopathy; TNF
,of considering a supply of exogenous l-arginine as an tumor necrosis factor-
; TTP, thrombocytopenic purpura.
alternative approach to control microangiopathies.
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